The changing epidemiology of the ageing thalassaemia populations: A new position statement by TIF
Therapeutic advances in β-thalassaemia have gradually led to a significant improvement in prognosis over the past few decades.
As a result, patients living in areas where disease specific programmes offer access to modern therapies, experience a new era of prolonged survival that tends to reach that of the normal population. Clinical management of ageing thalassaemia populations needs to be updated to include monitoring for age-related comorbidities for their timely diagnosis and treatment.
In this position paper of the Thalassaemia International Federation, TIF Executive Director, Dr Androulla Eleftheriou and TIF Medical Advisors, Dr Michael Angastiniotis, Dr Dimitrios Farmakis, and Dr Anastasios Giakoumis, review the changing epidemiology and clinical spectrum of patients with β-thalassaemia and propose actions to be undertaken in order to address the emerging spectrum of comorbidities resulting from ageing.
Read the full paper
